INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3801, 7430, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3802, 7432, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3803, 10527, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3804, 12818, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3805, 12820, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3806, 22401, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3807, 22402, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3808, 27051, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3809, 27052, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3810, 29893, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3811, 33638, 'Lisinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3812, 7430, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3813, 7432, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3814, 10527, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3815, 12818, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3816, 12820, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3817, 22401, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3818, 22402, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3819, 27051, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3820, 27052, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3821, 29893, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3822, 33638, 'Lisinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3823, 5798, 'Lithium carbonate', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3824, 25225, 'Lithium carbonate', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3825, 5798, 'Lithium carbonate', 'Heart Diseases', 'Lithium should generally not be given to patients with significant cardiovascular disease since the risk of lithium toxicity is high in these patients.  Additionally, there have been postmarketing reports of a possible association between lithium therapy and the unmasking of Brugada Syndrome, a disorder characterized by abnormal EKG findings and a risk of sudden death.  Lithium should be avoided in patients with this diagnosis or suspicion of it, or that have risk factors, which include unexplained syncope, family history of this syndrome, or family history of unexplained sudden death before the age of 45 years.  Therapy with lithium should be administered with extreme caution in patients with preexisting cardiac disease.  Consultation with a cardiologist is highly recommended and cardiac monitoring should be completed before and during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3826, 25225, 'Lithium carbonate', 'Heart Diseases', 'Lithium should generally not be given to patients with significant cardiovascular disease since the risk of lithium toxicity is high in these patients.  Additionally, there have been postmarketing reports of a possible association between lithium therapy and the unmasking of Brugada Syndrome, a disorder characterized by abnormal EKG findings and a risk of sudden death.  Lithium should be avoided in patients with this diagnosis or suspicion of it, or that have risk factors, which include unexplained syncope, family history of this syndrome, or family history of unexplained sudden death before the age of 45 years.  Therapy with lithium should be administered with extreme caution in patients with preexisting cardiac disease.  Consultation with a cardiologist is highly recommended and cardiac monitoring should be completed before and during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3827, 5798, 'Lithium carbonate', 'Dehydration', 'Lithium reduces the ability of the kidney to concentrate urine and produces a mild diabetes insipidus and polyuria.  Therefore, patients with preexisting dehydration are more prone to lithium retention and toxicity.  Therapy with lithium should be administered cautiously in dehydrated patients and may need to be discontinued until improvement in hydration status.  Careful monitoring of lithium levels are recommended.  Patients with sweating, diarrhea or concomitant infection with fever may need a temporary reduction or cessation of medication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3828, 25225, 'Lithium carbonate', 'Dehydration', 'Lithium reduces the ability of the kidney to concentrate urine and produces a mild diabetes insipidus and polyuria.  Therefore, patients with preexisting dehydration are more prone to lithium retention and toxicity.  Therapy with lithium should be administered cautiously in dehydrated patients and may need to be discontinued until improvement in hydration status.  Careful monitoring of lithium levels are recommended.  Patients with sweating, diarrhea or concomitant infection with fever may need a temporary reduction or cessation of medication.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3829, 5798, 'Lithium carbonate', 'Diarrhea', 'The risk for lithium toxicity may be increased in patients with diarrhea and excessive sweating.  Dehydration and sodium depletion may occur in these patients leading to lithium retention and toxicity.  The use of lithium may need to be reduced or suspended until the condition resolves.  Supplemental fluid and salt may need to be administered.  Monitoring serum lithium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3830, 25225, 'Lithium carbonate', 'Diarrhea', 'The risk for lithium toxicity may be increased in patients with diarrhea and excessive sweating.  Dehydration and sodium depletion may occur in these patients leading to lithium retention and toxicity.  The use of lithium may need to be reduced or suspended until the condition resolves.  Supplemental fluid and salt may need to be administered.  Monitoring serum lithium levels is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3831, 5798, 'Lithium carbonate', 'Hypothyroidism', 'The use of lithium has been associated with hypothyroidism in 5% to 15% of patient as it blocks the release of thyroxine (T4) and triiodothyronine (T3) mediated by thyrotropin.  Therapy with lithium should be administered cautiously in patients with preexisting hypothyroidism.  Careful monitoring of the thyroid function is recommended and supplemental thyroid treatment may be required.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3832, 25225, 'Lithium carbonate', 'Hypothyroidism', 'The use of lithium has been associated with hypothyroidism in 5% to 15% of patient as it blocks the release of thyroxine (T4) and triiodothyronine (T3) mediated by thyrotropin.  Therapy with lithium should be administered cautiously in patients with preexisting hypothyroidism.  Careful monitoring of the thyroid function is recommended and supplemental thyroid treatment may be required.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3833, 5798, 'Lithium carbonate', 'Kidney Diseases', 'Lithium is primarily eliminated by the kidneys and should generally not be administered to patients with significant renal dysfunction.  Additionally, morphological changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy, although the association has not been clearly established.  Kidney function should be assessed in patients prior to starting therapy, during and thereafter and routine urinalysis and renal function tests are recommended.  Progressive or sudden changes in renal function indicate the need for reevaluation of treatment.  Monitoring lithium serum levels is also recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3834, 25225, 'Lithium carbonate', 'Kidney Diseases', 'Lithium is primarily eliminated by the kidneys and should generally not be administered to patients with significant renal dysfunction.  Additionally, morphological changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy, although the association has not been clearly established.  Kidney function should be assessed in patients prior to starting therapy, during and thereafter and routine urinalysis and renal function tests are recommended.  Progressive or sudden changes in renal function indicate the need for reevaluation of treatment.  Monitoring lithium serum levels is also recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3835, 5798, 'Lithium carbonate', 'Water Intoxication', 'Lithium decreases sodium reabsorption by the renal tubules which could lead to sodium depletion.  Therapy with lithium should be administered cautiously in patients with preexisting sodium depletion as the risk of lithium toxicity is increased.  Lower dosages may be required.  Patients should maintain a normal diet, including salt, and an adequate fluid intake.  Monitoring lithium serum concentrations is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3836, 25225, 'Lithium carbonate', 'Water Intoxication', 'Lithium decreases sodium reabsorption by the renal tubules which could lead to sodium depletion.  Therapy with lithium should be administered cautiously in patients with preexisting sodium depletion as the risk of lithium toxicity is increased.  Lower dosages may be required.  Patients should maintain a normal diet, including salt, and an adequate fluid intake.  Monitoring lithium serum concentrations is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3837, 5798, 'Lithium carbonate', 'Neuroleptic Malignant Syndrome', 'Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with the use of antipsychotic drugs.  The diagnostic evaluation is complicated and the management requires immediate discontinuation of the antipsychotic therapy and intensive symptomatic treatment and medical monitoring.  If a patient that has recovered from NMS requires antipsychotic drug treatment again, the reintroduction of therapy should be carefully considered as NMS recurrences have been reported.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3838, 25225, 'Lithium carbonate', 'Neuroleptic Malignant Syndrome', 'Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with the use of antipsychotic drugs.  The diagnostic evaluation is complicated and the management requires immediate discontinuation of the antipsychotic therapy and intensive symptomatic treatment and medical monitoring.  If a patient that has recovered from NMS requires antipsychotic drug treatment again, the reintroduction of therapy should be carefully considered as NMS recurrences have been reported.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3839, 5798, 'Lithium carbonate', 'Epilepsy', 'Antipsychotics can lower the seizure threshold and trigger seizures in a dose-dependent manner.  Seizures have been reported in patients receiving antipsychotic therapy and may occur in epileptic patients even with maintenance of routine anticonvulsant treatment.  Therapy with antipsychotics should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  High dosages should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3840, 25225, 'Lithium carbonate', 'Epilepsy', 'Antipsychotics can lower the seizure threshold and trigger seizures in a dose-dependent manner.  Seizures have been reported in patients receiving antipsychotic therapy and may occur in epileptic patients even with maintenance of routine anticonvulsant treatment.  Therapy with antipsychotics should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  High dosages should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3841, 5798, 'Lithium carbonate', 'Fever', 'Patients with fever may have a lower tolerance to lithium due to increased fluid and sodium loss.  Lithium dosage may need to be reduced or suspended in such patients.  Monitoring lithium serum levels is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3842, 25225, 'Lithium carbonate', 'Fever', 'Patients with fever may have a lower tolerance to lithium due to increased fluid and sodium loss.  Lithium dosage may need to be reduced or suspended in such patients.  Monitoring lithium serum levels is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3843, 5798, 'Lithium carbonate', 'Hyperprolactinemia', 'Antipsychotic drugs can elevate serum prolactin concentrations, and this elevation persists during chronic administration.  This should be considered if therapy will be prescribed in patients with previously detected breast cancer as one-third of human breast cancers are prolactin-dependent in vitro.  Associated disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported.  Appropriate laboratory testing and follow-up is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3844, 25225, 'Lithium carbonate', 'Hyperprolactinemia', 'Antipsychotic drugs can elevate serum prolactin concentrations, and this elevation persists during chronic administration.  This should be considered if therapy will be prescribed in patients with previously detected breast cancer as one-third of human breast cancers are prolactin-dependent in vitro.  Associated disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported.  Appropriate laboratory testing and follow-up is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3845, 5798, 'Lithium carbonate', 'Neutropenia', 'The use of antipsychotics has been associated with events of leukopenia, neutropenia and agranulocytosis.  Possible risk factors include preexisting low white blood cell count, and history of drug induced leukopenia/neutropenia.  Patients with these risk factors should have complete blood count monitored frequently during the first few months of therapy.  Patients should also be monitored for any signs or symptoms of infection.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count or severe neutropenia (ANC < 1000/mm3).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3846, 25225, 'Lithium carbonate', 'Neutropenia', 'The use of antipsychotics has been associated with events of leukopenia, neutropenia and agranulocytosis.  Possible risk factors include preexisting low white blood cell count, and history of drug induced leukopenia/neutropenia.  Patients with these risk factors should have complete blood count monitored frequently during the first few months of therapy.  Patients should also be monitored for any signs or symptoms of infection.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count or severe neutropenia (ANC < 1000/mm3).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3847, 0, 'Loracarbef', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3848, 0, 'Loracarbef', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3849, 0, 'Loracarbef', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3850, 0, 'Loracarbef', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3851, 2702, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3852, 2703, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3853, 7525, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3854, 7530, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3855, 8338, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3856, 13780, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3857, 13784, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3858, 13785, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3859, 20512, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3860, 22027, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3861, 22030, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3862, 22031, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3863, 22032, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3864, 22033, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3865, 22041, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3866, 22993, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3867, 26628, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3868, 26629, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3869, 26681, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3870, 28731, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3871, 28732, 'Loratadine', 'Liver Diseases', 'Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation.  The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min).  Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3872, 0, 'Lonafarnib', 'Liver Diseases', 'Hepatic transaminase elevations (i.e., aspartate aminotransferase AST] and alanine aminotransferase ([ALT]) have been reported during lonafarnib therapy.  Often these elevations improve with continued therapy, but it is not possible to exclude this drug as a cause of the abnormalities.  Liver enzymes should be monitored periodically during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3873, 0, 'Lonafarnib', 'Neurotoxicity Syndromes', 'Lonafarnib has not been studied in patients with renal impairment, however, this drug caused nephrotoxicity in rats at plasma drug exposures approximately equal to that achieved with the human dose.  Renal function should be monitored at regular intervals during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3874, 871, 'Lorazepam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3875, 871, 'Lorazepam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3876, 871, 'Lorazepam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3877, 871, 'Lorazepam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3878, 871, 'Lorazepam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3879, 871, 'Lorazepam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3880, 871, 'Lorazepam', 'Hypotension', 'Benzodiazepines should not be administered by injection to patients in shock or coma.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3881, 871, 'Lorazepam', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3882, 871, 'Lorazepam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3883, 871, 'Lorazepam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3884, 871, 'Lorazepam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3885, 871, 'Lorazepam', 'Gastrointestinal Diseases', 'The manufacturer recommends the use of caution when prescribing lorazepam for prolonged periods in patients with upper gastrointestinal disease, especially in the elderly.  The appearance or worsening of upper gastrointestinal symptoms should be monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3886, 0, 'Liotrix', 'Adrenal Insufficiency', 'The use of thyroid hormones is contraindicated in patients with uncorrected adrenal insufficiency.  Thyroid hormones increase tissue demand for adrenocortical hormones and may precipitate acute adrenal crisis.  In patients with controlled adrenal insufficiency or other endocrine disorders, therapy for these concomitant disorders may need to be adjusted following thyroid replacement, since hypothyroidism often obscure or diminish the signs and symptoms of these conditions.  Clinical monitoring of thyroid and adrenal function as well as any other appropriate endocrine function is recommended during thyroid hormone therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3887, 0, 'Liotrix', 'Cardiovascular Diseases', 'Thyroid hormones cause increases in myocardial contractility and heart rate as a result of increased metabolic demands and oxygen consumption.  Therapy with thyroid hormones should be administered cautiously and initiated at reduced dosages in patients with cardiovascular disorders such as angina, coronary artery disease, and hypertension.  Clinical monitoring of cardiovascular function is recommended.  If chest pain or exacerbation of cardiovascular disease occurs, the dosage of thyroid hormone should be reduced, even at the expense of achieving euthyroid state.  Thyroid hormones should not be administered to patients with an acute myocardial infarction that is not complicated by hypothyroidism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3888, 0, 'Liotrix', 'Graves Disease', 'The use of thyroid hormones is contraindicated in patients with untreated thyrotoxicosis of any etiology, since thyroid hormones may exacerbate the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3889, 0, 'Liotrix', 'Diabetes Mellitus', 'Since hypothyroidism often obscure or diminish the signs and symptoms of endocrine disorders such as diabetes mellitus or diabetes insipidus, thyroid replacement therapy may aggravate the intensity of symptoms associated with these conditions.  Patients with endocrine disorders should be monitored more closely during thyroid hormone therapy, and their medication regimen adjusted accordingly.  If thyroid medication is later discontinued, a downward readjustment of insulin or oral hypoglycemic agent may be necessary in patients with diabetes mellitus to avoid hypoglycemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3890, 0, 'Liotrix', 'Seizures', 'Thyroid hormones may alter the seizure threshold.  Seizures have been reported rarely following the initiation of levothyroxine therapy.  Therapy with thyroid hormones should be administered cautiously in patients predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3891, 0, 'Lorcaserin', 'Heart Valve Diseases', 'Regurgitant cardiac valvular disease, primarily affecting the mitral and/or aortic valves, has been reported in patients who took serotonergic drugs with 5-HT2B receptor agonist activity.  The etiology is thought to involve activation of 5-HT2B receptors on cardiac interstitial cells.  At therapeutic concentrations, lorcaserin is selective for 5-HT2C receptors relative to 5-HT2B receptors, thus it is not known if lorcaserin can cause valvulopathy.  In clinical trials of one year duration, 2.4% of patients receiving lorcaserin and 2.0% of patients receiving placebo developed echocardiographic criteria for valvular regurgitation at one year (mild or greater aortic regurgitation and/or moderate or greater mitral regurgitation).  None of these patients was symptomatic.  Lorcaserin has not been studied in patients with congestive heart failure or hemodynamically-significant valvular heart disease.  Preliminary data suggest that 5-HT2B receptors may be overexpressed in congestive heart failure.  Therapy with lorcaserin should be administered cautiously in patients with congestive heart failure or preexisting valvulopathy.  Patients who develop signs and symptoms of valvular heart disease such as dizziness, fatigue, weakness, dyspnea, edema, or arrhythmia during treatment with lorcaserin should seek prompt medical attention.  Discontinuation of lorcaserin should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3892, 0, 'Lorcaserin', 'Bradycardia', 'Lorcaserin may decrease heart rate.  In clinical trials of at least one year duration, the mean decrease in heart rate was 1.2 beats per minute (bpm) in lorcaserin-treated and 0.4 bpm in placebo-treated patients without diabetes, and 2.0 bpm in lorcaserin-treated and 0.4 bpm in placebo-treated patients with type 2 diabetes.  The incidence of heart rate less than 50 bpm was 5.3% in lorcaserin-treated and 3.2% in placebo-treated patients without diabetes, and 3.6% in lorcaserin-treated and 2.0% in placebo-treated patients with type 2 diabetes.  In the combined population, adverse reactions of bradycardia occurred in 0.3% of lorcaserin-treated and 0.1% of placebo-treated patients.  Therapy with lorcaserin should be administered cautiously in patients with bradycardia or a history of heart block greater than first degree.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3893, 0, 'Lorcaserin', 'Breast Neoplasms', 'Lorcaserin can cause elevations in prolactin.  In clinical trials of at least one year duration, elevations of prolactin greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal occurred in 6.7%, 1.7%, and 0.1% of lorcaserin-treated patients, compared to 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively.  One patient treated with lorcaserin developed a prolactinoma.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term lorcaserin therapy is unknown.  Chronic administration of other prolactin-stimulating drugs (e.g., neuroleptics, phenothiazines) has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with lorcaserin should be administered cautiously in patients with a previously detected breast cancer.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3894, 0, 'Lorcaserin', 'Depressive Disorder', 'Drugs like lorcaserin that target the central nervous system have been associated with depression and suicidal ideation.  Psychiatric events of euphoria, hallucination, and dissociation were observed with lorcaserin at supratherapeutic dosages in short-term studies.  In clinical trials of at least one year duration, 0.2% of patients treated with lorcaserin developed euphoria, compared to <0.1% treated with placebo.  Therapy with lorcaserin should be administered cautiously in patients with preexisting depression or psychiatric illnesses.  Lorcaserin dosage should not exceed 10 mg twice a day, and patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.  Lorcaserin should be discontinued in patients who experience suicidal thoughts or behavior.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3895, 0, 'Lorcaserin', 'Hematologic Diseases', 'Hematological changes, including decreases in hemoglobin and hematocrit counts, have been reported with the use of lorcaserin.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  It is recommended to consider periodic monitoring of complete blood count during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3896, 0, 'Lorcaserin', 'Liver Diseases', 'Lorcaserin is extensively metabolized in the liver by multiple enzymatic pathways.  In study subjects with varying degrees of hepatic function, lorcaserin peak plasma concentration (Cmax) was reduced by 7.8% and 14.3% in subjects with mild (Child-Pugh score 5 to 6) and moderate (Child-Pugh score 7 to 9) hepatic impairment, respectively, compared to subjects with normal hepatic function.  Lorcaserin exposure (AUC) increased by approximately 22% and 30% in patients with mild and moderate hepatic impairment, respectively, and the half-life was prolonged by 59% to 19 hours in patients with moderate hepatic impairment.  No dosage adjustment of lorcaserin is required in patients with mild to moderate hepatic impairment.  The effect of severe hepatic impairment on the pharmacokinetics of lorcaserin was not evaluated.  Therapy with lorcaserin should be administered cautiously in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3897, 0, 'Lorcaserin', 'Priapism', 'Lorcaserin may cause priapism due to 5-HT2C receptor agonism.  The condition is characterized by prolonged, often painful erections lasting longer than 4 hours.  If not treated promptly, priapism can cause irreversible damage to the erectile tissue.  Therapy with lorcaserin should be administered cautiously in patients with a history of priapism, conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia, thalassemia), or anatomical deformations of the penis (e.g., angulation, cavernosal fibrosis, Peyronie''s disease).  Patients who experience an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3898, 0, 'Lorcaserin', 'Hypertension, Pulmonary', 'Lorcaserin is believed to promote satiety by selectively activating serotonin 2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus.  Certain centrally-acting weight loss agents that act on the serotonin system have been associated with pulmonary hypertension, a rare but lethal disease.  Care should be taken when prescribing this drug to patients at risk or with pulmonary hypertension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3899, 0, 'Lorcaserin', 'Kidney Diseases', 'Lorcaserin is extensively metabolized in the liver by multiple enzymatic pathways, and the metabolites are primarily eliminated by the kidney.  In patients with varying degrees of renal function, lorcaserin systemic exposure (AUC) was not significantly different, but AUC of the sulfamate metabolite (M1) was increased by approximately 1.7-fold in mild (CrCl 50 to 80 mL/min), 2.3-fold in moderate (CrCl 30 to 50 mL/min), and 10.5-fold in severe renal impairment (CrCl <30 mL/min) compared to normal renal function (CrCl >80 mL/min), while AUC of the N-carbamoyl-glucuronide metabolite (M5) was increased by approximately 1.5-, 2.5-, and 5.1-fold, respectively.  No dosage adjustment of lorcaserin is required in patients with mild renal impairment, but caution is advised when used in patients with moderate renal impairment.  Use in patients with severe renal impairment or end stage renal disease is not recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3900, 0, 'Lorcaserin', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', '', 'DDInter', 0);
